Bristol-Myers Squibb Company (BMY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors – 2nd Annual Healthcare Forum Transcript

Courtney Breen
Sanford C. Bernstein & Co., LLC., Research Division

Thank you all so much for being here. And Lynelle, thank you so much for being here with us today. For those of you who don’t know me, my name is Courtney Breen. I am the large-cap analyst here at Bernstein covering all of our U.S. names, Bristol included. And I am very, very proud and happy to share the stage today with Lynelle here from Bristol. She is the Head of the cell therapy business. And we’re going to have a bit of a conversation around kind of particularly the potential in cell therapy, how it’s landing in the hematology space, predominantly where it is today, where it might be going in the future.

And so really, really excited to talk about this because I think we’ve got some proof points now, but there’s a lot of innovation on the horizon, which is really, really exciting. Perhaps before we dig into that, I’d love to hear, Lynelle, you just open with a couple of comments from your side. Anything you want to say to set the stage and set some context about your background and the conversation we’re going to have.

Lynelle Hoch
President of Cell Therapy Organization

Yes. Well, first of all, thank you, Courtney, and thank you for Bernstein for having me and BMS represented here today. And certainly, I’m excited to have a 40-minute conversation about cell therapy. I have passionately been involved in this particular business for 4 years. And I think to myself, when I go back